TORONTO, ONTARIO--(Marketwired - May 6, 2016) - Abba Medix Group Inc. ("Abba Medix" or the "Company") (CSE:ABA) is pleased to provide a further update to shareholders regarding current operations.

As the medical marijuana industry continues to rapidly evolve in Canada, Abba Medix continues to stay focused on the forefront of opportunities that continue to exist. The foundation of the industry is based on cost effective production and patient acquisition. Abba Medix and the Board of Directors continue to aggressively pursue specific strategic acquisitions based on these criteria that would enhance shareholder value in the future.

Also, as previously announced, the Abba Medix's MMPR application is in final review stage with Health Canada and the Company anticipates to have the pre license inspection in the near future. The Company has invested millions of dollars to create a state of the art facility that exceeds all industry standards.

Abba Medix continues to work towards the expansion of the Board of Directors and management team to support the Company going forward. The Company will announce new appointments immediately as they happen.

Gerry Goldberg, Interim CEO of Abba Medix said, "Although I have only recently joined the company, I am confident that the course of action that we are implementing now, will drive shareholder value going forward."

Abba Medix will continue to provide regular updates regarding progress on its acquisition strategy and operations.

For more information about Abba Medix group, please visit

About Abba Medix Corp.

Abba Medix Group Inc. (CSE:ABA) is the parent company of Abba Medix Corp; a purveyor of fine medical marijuana in Canada. In compliance with Health Canada's regulations, the company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated medical marijuana marketplace. Abba's mission is to find, acquire or create joint venture opportunities in patient focused medical marijuana related companies, products, organizational events, sponsorships, educational training, and research and development within medical marijuana sector. For more information please visit

Cautionary Statements Regarding Forward-Looking Information

Certain statements within this press release relating to the Company constitute "forward-looking statements", within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and / or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are "forward-looking statements". Such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and / or sales of medical marijuana, quantities of future medical marijuana production, anticipated revenues in connection with such sales, the overall projected size of the market, completion and / or expansion of production facilities, and other information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. Actual results may differ materially from those expressed or implied by such forward-looking statements and involve risk and uncertainties relating to the Company's historical experience with medical marijuana operations, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, and other uninsured risks. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Further, there can be no assurance that Abba Medix's medical marijuana license application will be approved by Health Canada, or that any prospective projects in the industry will be successfully completed. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Abba Medix Group Inc.
Gerry Goldberg
Interim Chief Executive Officer